Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EDGAR: A Multicentre Prospective Observational Study Evaluating Dalbavancin Pharmacokinetics, Therapeutic Drug Monitoring and Clinical Outcomes in Serious Gram-Positive Bacterial Infections

NCT07858526 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT07858526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07858526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EDGAR: A Multicentre Prospective Observational Study Evaluating Dalbavancin Pharmacokinetics, Therapeutic Drug Monitoring and Clinical Outcomes in Serious Gram-Positive Bacterial Infections
Lead sponsor
Kirby Institute
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2029
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

serious gram-positive bacterial infections